Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Lost 13.4% in January

By George Budwell - Feb 4, 2020 at 7:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The mid-cap drugmaker's poor start to the year could be an outstanding buying opportunity for long-term investors.

What happened

Shares of Amarin (AMRN -1.82%), a mid-cap drugmaker, dropped by 13.4% last month, according to data from S&P Global Market Intelligence. Shares took a beating in January for two reasons:

First, Amarin has long been rumored to be a top buyout candidate. A worthwhile tender offer has yet to materialize, however. As a result, investors looking for a quick buck on a high-priced buyout appear to be moving on to greener pastures. 

Second, nearly all biotech stocks took a sizable downturn toward the tail end of January due to the growing concerns over the Wuhan coronavirus. The core reason is that this emerging viral pandemic is now expected to have a profound effect on the global economy in 2020.  

A chalkboard chart showing a positive trend turn negative.

Image source: Getty Images.

So what

With U.S. investors seemingly losing their appetite for risky pharma stocks last month and a buyout off the table for the moment, Amarin's sharp decline in January isn't altogether surprising. Before this sell-off, after all, the drugmaker's shares were trading at one of the richest premiums in the entire healthcare sector. 

The good news is that Amarin's valuation is now in bargain territory. The biopharma's shares, in fact, are currently trading at around three times the low-end peak sales estimate for its prescription omega-3 treatment Vascepa.  

Now what

Is Amarin stock a strong buy right now? While it still has its fair share of critics, Vascepa has no equal in the marketplace. So, given the sheer size of Vascepa's newly expanded label, there's no good reason to believe that Amarin won't eventually return to its winning ways. Bargain hunters, in kind, may want to scoop up some shares on the heels of this double-digit pullback.   

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.62 (-1.82%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.